In this episode, David Flores sits down with Cannara CFO Nicholas Sosiak, to discuss the Company's future goals and to spotlight what differentiates Cannara from other companies in the cannabis space.
Similar Posts
BIG MindMed MDMA Trial, Atai to Compete with Elon’s Neuralink ? (+ Updates on CMPS, MYCO and ENBI)
Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. Part Deux: ” BIG MindMed MDMA Trial, Atai’s to Compete with Tesla’s Neuralink (+Updates on CMPS, MYCO and ENBI)” might be a lot more interesting to some of you, however, I would suggest you watch Part I entitled: “HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?” That is if you are interested in the general developments in the psychedelic industry for this week.
In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.
1. We’ll cover some MindMed News [ MMED / MMEDF recently announced a new MDMA study ]
2. Atai Life Sciences’ Computer Brain Interface & their clinical trial to treat Schizophrenia
3. Compass Pathways (CMPS) has amazing new price targets
4. Mydecine (MYCO / MYCOF ) has progressed four new compounds towards clinical trials
5. Entheon’s (ENBI / ENTBF) new Genetic Test Kit Updates
​…
​Timestamps:
0:00​ – Intro
1:47 – MindMed’s (MMED / MMEDF / MMQ) Announcing New Data on Personalized MDMA Dosing
6:08 – Atai Life Sciences acquires Psyber Inc to develop Brain Computer Interface -enabled digital therapeutics targeting mental health disorder
8:00 – Atai’s Subsidiary, Recognify Life Sciences, to Commence Phase 2 clinical study in Cognitive Impairment associated with Schizophrenia
9:07 – Roth Capital Upgrades Compass Pathways (CMPS) price targets & CMPS has scheduled a corporate update
10:32 – Mydecine ( MYCOF / MYCO ) Announces Four New Lead Drug Candidates for Pre-IND Meetings with the FDA & Health Canada to prepare for clinical trials. ( MYCO 001, MYCO 002, MYCO 003 & MYCO 004 )
13:02 – Entheon Biomedical (ENBI / ENTBF ) has now launched Halugen’s Psychedelics’ Genetic KIT
So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this! As our thumbnail titles states: The SHROOM BOOM is REAL! Psychedelics are taking the world by storm and psychedelic inspired companies are releasing news every single day. We’ll try to cover most of them but if there’s a company you want us to cover more in debt, please let us know in the comments and we’ll try to satisfy your demands.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
​…
​
https://benzinga.grsm.io/thepsychedel
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed​​​​ ​#MMEDStock #CMPS Stock
The Mainstream Media GETS Psychedelic Stocks [Like MMEDF, CMPS, EHVVF & FTRPF]
Hello psychedelic investors! Today’s episode will be a little different. We will discuss the recent media coverage of psychedelic stocks and its role in psychedelic inspired companies’ future.
It appears that the mainstream media understands the potential for psychedelic stocks to disrupt the pharmaceutical Industry. Now understanding what this means, and its implications is extremely important for retail investors like you and me.
We’ll also zoom into one piece of media about MindMed (MMED/MMEDF) and Compass Pathways (CMPS), and explore how it hits the nail on the head.
We are going to do this because one, it’s a good article that I wanted to share with you
And two, it exemplifies my point that the mainstream understands the potential here, and might actually be on the right side of history.
P.S. I mention in the video that the article I’m discussing is by Yahoo Finance. It turns out the article is from OTC stock review.
For those interested in reading the entire article: https://ca.movies.yahoo.com/264-million-reasons-psychedelic-stocks-133000885.html
Time Stamps
0:00​ – Intro
3:10 – Media Coverage on Tesla & Psychedelic Stocks
6:36 – Benefits of the media covering Psychedelic Companies like (MMEDF & CMPS)
8:05 – Influence on stock valuations and stealth investors
10:57 – 264 Million Reasons Why Psychedelic Stocks Have More Room To Grow
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed​​ ​ #MindmedStock​​ #PsychedelicStocks
Dr. Matthew Johnson discusses Psychedelics, the Hard Problem of Consciousness and UFOs
During our time in Wonderland Miami, we had the pleasure to meet and interview Dr. Matthew Johnson of Johns Hopkins University. In this Psychedelic Spotlight Interview, we discuss a wide range of topics surrounding psychedelics and their effectiveness as treatments for ailments like tobacco addiction and PTSD. Of course, our conversation took as spin as we also touched on topics such as UFOs, DMT experiences and the CIA!
Timestamps:
0:00 – Intro
1:10 – Dr. Johnson’s latest updates on treating smoking cessation with psilocybin
6:55 – MAPS’ study using MDMA to treat PTSD
7:20 – DMT’S mystical experiences of perceiving aliens, machine elves and autonomous beings
13:08 – CIA research on psychedelics for telepathy and remote viewing
15:01 – What is consciousness?
19:02 – The intriguing evidence of UFOs?
21:40 – Where do we see psychedelics going in the next 5 years?
Make sure to like, share and subscribe if you enjoyed this episode!
#Psychedelics #MatthewJohnson #UFO
MindMed ‘s Plan to END the Opioid Epidemic (How MMED / MMEDF Could Make Billions)
It is an unfortunate fact that the world is dealing with a second hidden epidemic: The Opioid Crisis. Luckily, MindMed ( MMED/ MMEDF ) has a solution: 18-MC. This Psychedelic Medicines company, which may soon be uplisted to the Nasdaq, is testing it’s ibogaine derivative to heal those effected by opioid addiction, whether from fentanyl or doctors’ prescriptions. We may have a light at the end of the tunnel, and the Opioid Epidemic may be defeated. This makes MindMed one of the best stocks for 2021. How much could this be worth? Tune in to find out!
Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
Resources
https://www.cdc.gov/nchs/pressroom/podcasts/20190911/20190911.htm
https://www.ncbi.nlm.nih.gov/books/NBK541390/#:~:text=Morethan2millionpeople,diseasestraumaandsuicide.
https://www.hhs.gov/opioids/about-the-epidemic/opioid-crisis-statistics/index.html#:~:text=In2018anestimated10.3,and808000peopleusedheroin.&text=Appropriateprescribingofopioidsis,andsafetyofMedicarebeneficiaries.
https://www.ccsa.ca/opioids#:~:text=Canadaisinthemidst,publichealthandsafetyconcern.
https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.17477
https://www.publichealthontario.ca/-/media/documents/o/2020/opioid-mortality-covid-surveillance-report.pdf?la=en
https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/opioid-addiction
https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery
https://preprod.drugfree.org/article/relapse-overdose/
https://mindmed.co/psychedelic-inspired/#scroll_section-1
https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine
https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine
https://s3.ca-central-1.amazonaws.com/ibosafe-pdf-resources/Ibogaine/Treating+drug+dependence+with+the+aid+of+ibogaine_a+retrospective+study.pdf
https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine
https://thethirdwave.co/psychedelics/ibogaine/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382526/#:~:text=Theantiaddictiondrugibogainecertainlyaffectstheheartand,ibogaine’spotentiallylifethreateningcardiotoxicity.
https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
https://www.ibogainealliance.org/18-mc/
https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
#MindMed #MMED #MMEDF #MindMedNews #OpioidEpidemic #OpioidCrisis #MindMedStock #18MC #18-MC #PsychedelicStocks
Top 10 Psychedelic Stocks To Own According To PSIL ETF (MNMD, CMPS, ATAI, NUMI & MORE)
Top 10 Psychedelic stocks to own according to PSIL ETF (DO I AGREE?)
What’s up Psychedelic Investors!?! Today we are looking at the actively managed Psychedelic Medicines ETF, PSIL, run by Advisor Shares.
Before we get into that though, make sure you go check out psychedelicspotlight.com and sign up for their weekly newsletter. I am featured in each one, with a 3:30 clip summarizing the biggest events in the psychedelic medicines world over the past week. It is essential!
On today’s episode we go through each of the top ten holding in PSIL, including MindMed (MNMD /MMED), Compass Pathways (CMPS), atai Life Sciences (atai), Cybin (CYBN), Field Trip (FTRP), Numinus, (NUMI) and more.
For some of the lesser known companies, such as Seelos Therapeutics, Wesana Health and GreenBrook TMS, we give a brief rundown of the company.
Investing in an actively managed psychedelic stocks ETF can be a great opportunity for those who believe in the ability of psychedelics to heal mental health issues such as PTSD and depression, but are not sure which companies are best to invest in. PSIL is actively managed, which means that their team of experts are picking what they believe to be the best stocks in the industry.
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PSIL #ThePsychedelicInvestor
MindMed (MMED) Cluster Headaches LSD Trials Update (and response to criticisms)
Hey guys! Here is an Update and response to our easily most controversial video “MindMed (MMED) Suicide Headaches trial VANISHES from Website ( What Happened?)”. We got a response from MindMed while also receiving some backlash from the MindMed investors community that will be addressed. Hope you guys find some value in this video. I appreciate you guys. LOOVE all comments and criticisms. Caio!
P.S. S/O to Magic Shrooms who also contributed by commenting that he “received a reply from MMED concerning about the cluster headaches trial. they said that there has been no changes in regard to their on-going trial using LSD for suicide headaches!”
Just to let you know, we temporarily (perhaps permanently?) have removed the first video, while we discuss how to move forward.
Subscribe to our channel to get the latest updates on Psychedelic Stocks. Follow the MMED stock and other companies like it.
Let us know in the comments what you think about the new way we edited our video? Do you like it more than how we edited them previously?
🎵 Music: www.bensound.com
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #mmed #mindmedstock #psychedelicstocks #mmedf